Clinical trial · Observational
Attribution of Toxicities Due to Radiotherapy and Immuno-Biological Therapies
Attribution of Toxicities Due to Radiotherapy and Immuno-Biological Therapies - Registry
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Every year, new molecular agents enter the market with more and more patients receiving these treatments, especially in the metastatic setting. These molecular agents could correspond to immunotherapy and modulators of signaling pathways. More than 50% of cancer patients will receive radiation therapy during the course of their illness, including radiotherapy aimed a palliating symptoms secondary to metastatic diseases. Therefore, there will be an increasing number of patients who will be receiving radiotherapy while they are still receiving molecular agents. A better understanding of the interaction of these two treatment modalities is needed.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Radiotherapy Side Effect | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Combined modality
- description
- Patients receiving radiotherapy and a molecular agent for the treatment of cancer
- interventionNames
- Radiation: Radiotherapy
Primary outcomes (1)
- measure
- Number of Participants with severe side effects
- timeFrame
- 1 year
- description
- CTCAE V5 Grade 3-5 toxicities
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Consent to be part of the AtTRIBut registry * Prior histological diagnosis of primary cancer. * If the patient has metastatic disease, there must be radiological or pathological evidence of metastasis * Age\> 18 years * Receiving a molecular therapy * Indicated to receive radiotherapy * Radiation therapy can be administered using 3D conventional, IMRT or SBRT techniques. Exclusion Criteria: • Refusal or inability to receive radiotherapy
References
Publications (0)
Data not yet available